RDF/XMLNTriplesTurtleShow queryShare
SubjectPredicateObject
http://purl.uniprot.org/citations/25267273http://www.w3.org/1999/02/22-rdf-syntax-ns#typehttp://purl.uniprot.org/core/Journal_Citation
http://purl.uniprot.org/citations/25267273http://www.w3.org/2000/01/rdf-schema#comment"Cancer stem-like cells/cancer-initiating cells (CSCs/CICs) are considered to represent a small population of cancer cells that is resistant to conventional cancer treatments and responsible for tumor recurrence and metastasis. The aim of this study was to establish CSC/CIC-targeting immunotherapy. In this study, we found that Annexin A3 (ANXA3) was preferentially expressed in CSCs/CICs derived from hepatocellular carcinoma (HCC) cells compared to non-CSCs/CICs. In HCC samples, high levels of ANXA3 correlated with expansion of CD133(+) tumor cells representing CSCs/CICs in HCC; the combination of high levels of ANXA3 and CD133 was associated with progression of HCC. Overexpression of ANXA3 increased the proportion of CD133(+) cells, enhancing their tumorigenicity. On the contrary, knockdown of ANXA3 decreased CD133(+) cells and inhibited tumorigenicity. The mechanistic study revealed that ANXA3-mediated maintenance of HCC CSCs/CICs activity was likely involved with the HIF1A/Notch pathway. Using ANXA3 as a target, ANXA3-transfected dendritic cells could induce more functionally active T cells and these effector T cells could superiorly kill CD133(+) HCC CSCs/CICs in vitro and in vivo. Taken together, our findings suggest that ANXA3 plays a role in HCC CSC/CIC maintenance, and that ANXA3 may represent a potential CSC/CIC-specific therapeutic target for improving the treatment of HCC."xsd:string
http://purl.uniprot.org/citations/25267273http://purl.org/dc/terms/identifier"doi:10.1002/stem.1850"xsd:string
http://purl.uniprot.org/citations/25267273http://purl.uniprot.org/core/author"He J."xsd:string
http://purl.uniprot.org/citations/25267273http://purl.uniprot.org/core/author"Liu Q."xsd:string
http://purl.uniprot.org/citations/25267273http://purl.uniprot.org/core/author"Tang Y."xsd:string
http://purl.uniprot.org/citations/25267273http://purl.uniprot.org/core/author"Zhang X.F."xsd:string
http://purl.uniprot.org/citations/25267273http://purl.uniprot.org/core/author"Chen C.L."xsd:string
http://purl.uniprot.org/citations/25267273http://purl.uniprot.org/core/author"Lv L."xsd:string
http://purl.uniprot.org/citations/25267273http://purl.uniprot.org/core/author"Pan K."xsd:string
http://purl.uniprot.org/citations/25267273http://purl.uniprot.org/core/author"Jiang S.S."xsd:string
http://purl.uniprot.org/citations/25267273http://purl.uniprot.org/core/author"Zhang H.X."xsd:string
http://purl.uniprot.org/citations/25267273http://purl.uniprot.org/core/author"Zheng H.X."xsd:string
http://purl.uniprot.org/citations/25267273http://purl.uniprot.org/core/author"Li Y.Q."xsd:string
http://purl.uniprot.org/citations/25267273http://purl.uniprot.org/core/author"Zhao J.J."xsd:string
http://purl.uniprot.org/citations/25267273http://purl.uniprot.org/core/author"Wang Q.J."xsd:string
http://purl.uniprot.org/citations/25267273http://purl.uniprot.org/core/author"Pan Q.Z."xsd:string
http://purl.uniprot.org/citations/25267273http://purl.uniprot.org/core/author"Weng D.S."xsd:string
http://purl.uniprot.org/citations/25267273http://purl.uniprot.org/core/author"Xia J.C."xsd:string
http://purl.uniprot.org/citations/25267273http://purl.uniprot.org/core/date"2015"xsd:gYear
http://purl.uniprot.org/citations/25267273http://purl.uniprot.org/core/name"Stem Cells"xsd:string
http://purl.uniprot.org/citations/25267273http://purl.uniprot.org/core/pages"354-366"xsd:string
http://purl.uniprot.org/citations/25267273http://purl.uniprot.org/core/title"Annexin A3 as a potential target for immunotherapy of liver cancer stem-like cells."xsd:string
http://purl.uniprot.org/citations/25267273http://purl.uniprot.org/core/volume"33"xsd:string
http://purl.uniprot.org/citations/25267273http://www.w3.org/2004/02/skos/core#exactMatchhttp://purl.uniprot.org/pubmed/25267273